Skip to content

Clinical observation study of acute hepatitis E complicated with hepatitis B infection

Clinical observation study of acute hepatitis E complicated with hepatitis B infection

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065894
Enrollment
Unknown
Registered
2022-11-17
Start date
2022-12-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HEV, HBV

Interventions

Case series:N/A

Sponsors

The Third Hosptial of Zhenjiang Affiliated Jiangsu University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1. No age or gender limitation; 2. Diagnostic criteria: according to the Clinical Diagnosis and Treatment Guidelines of Chinese Medical Association, Infectious Diseases Volume (December 2006, People's Medical Publishing House): (1) Acute onset; (2) Epidemiology: Eating uncooked seafood or drinking contaminated water in hepatitis E endemic areas before the onset of the disease; (3) Main symptoms: fatigue, loss of appetite, nausea, vomiting, oil aversion, abdominal distension, liver pain, urine color, jaundice, a few can be accompanied by fever; (4) Main signs: yellow staining of skin and sclera, large liver, soft texture, sharp edges, tenderness and tapping pain; (5) Etiology: Hepatitis E virus (HEV) related tests were positive, in which the positive blood or stool HEV-RNA (+) was of diagnostic significance, and the positive anti-HEV-igm and/or anti-HEV-igg (+) were of reference value; (6) Other causes of acute liver injury caused by hepatitis A virus, other hepatotropic viruses such as cytomegalovirus and drugs were excluded; According to the above criteria (1)~(4), (6) and positive anti-HEV-IgM (+), clinical diagnosis can be made. Positive blood or stool HEV-RNA (+) can confirm the diagnosis.

Exclusion criteria

Exclusion criteria: 1. Incomplete clinical data; 2. Patients with mental disorders or other serious diseases.

Design outcomes

Primary

MeasureTime frame
glutamic-pyruvic transaminase;glutamic oxalacetic transaminase;TBil (total bilirubin);INR (International normalized ratio);HEV IgM;HEV IgG;second liver two half-and-half;HBV DNA;blood routine examination;

Countries

China

Contacts

Public ContactTan Youwen

The Third Hosptial of Zhenjiang Affiliated Jiangsu University

tyw915@sina.com+86 13914567088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026